Source: Annual Congress 2011 - Role of the biomarkers in airway diseases
Disease area: Airway diseases, Respiratory infections

Abstract

Introduction
Colonisation or infection of airways from bronchiectasis patients by Pa results in chronic inflammation leading to a progressive destruction of the lung and to a decline in lung function. Therefore more inpatient stays for intravenous antibiotic treatment are necessary and the quality of life in these patients is severely limited.
Objectives
Aim of our study was to detect and compare volatile organic compounds (VOCs) by IMS in exhaled breath of bronchiectasis patients either colonised or infected by Pa with healthy non-smoking controls (hc).
Methods
We have analysed VOCs by IMS coupled to a multi-capillary column (MCC) for pre-separation (MCC-IMS, B&S Analytik) in exhaled breath of bronchiectasis patients either colonised (Pac,n=3) or infected (Pai,n=9) by Pa (Pac+Pai=Pa+,n=12) compared to hc (n=39) and compared Pac with Pai. In addition we analysed VOCs from Pa cultures growing on agar plates.
Results
Using IMS for VOC analysis, differences between Pa+ and hc could be found. Different peaks were detected between Pac and hc, Pai and hc as well as Pac and Pai. VOC analysis from Pa cultures revealed two peaks which could be found in the Pa+ bronchiectasis patients.
Conclusions
IMS seems to be a promising method for the non-invasive identification of patients which are colonized or infected with Pa. A differentiation between patients colonised or infected with Pa seems to be possible, as well. However, confirmation of our findings in a larger study population is needed. The comparison of Pa+ with Pa cultures will help to identify peaks caused by the presence of Pa. Furthermore, it is required to identify the molecules representing the peaks.

Rating:

Share or cite this content

Citations should be made in the following way:
T. Rabis, O. Anhenn, J. I. Baumbach, I. Kurth, G. Weinreich, H. Teschler, L. Freitag, K. Darwiche, U. Mellies, P. M. Rath, U. Sommerwerck (Essen, Saarbrücken, Germany). Detection of pseudomonas aeruginosa (Pa) specific peaks by ion mobility spectrometry (IMS) in exhaled breath of bronchiectasis patients. Eur Respir J 2011; 38: Suppl. 55, 4790

Member's Comments

No comment yet.

Related content which might interest you: Clusters of biomarkers in exhaled breath detected by differential ion mobility spectrometry (DMS) Source: Annual Congress 2011 - Bronchial hyperresponsiveness and exhaled and sputum biomarkers Year: 2011 Detection of differences in volatile organic compounds (VOCs) by ion mobility spectrometry (IMS) of exhaled breath in patients with interstitial lung diseases (ILDs) compared to healthy controls (HC) Source: Annual Congress 2011 - Bronchoalveolar lavage and biomarkers in diffuse parenchymal lung disease Year: 2011 Differentialion mobility spectrometry (DMS) for discrimination of local gut infection in exhaled breath Source: Annual Congress 2010 - Exhaled biomarkers: smells like disease Year: 2010 Detection of infectious agents in the airways by ion mobility spectrometry in exhaled breath Source: Annual Congress 2010 - Mechanisms of respiratory infections Year: 2010 Exhaled breath analysis for the detection of Streptococcus pneumoniae and Pseudomonas aeruginosa lung infections using gas chromatography – mass spectrometry: a rat model study. Source: International Congress 2018 – Mechanisms of respiratory infection Year: 2018 Detection of pregnancy in horses by breath analysis using differential ion mobility spectrometry (DMS) Source: Annual Congress 2011 - Lung function today and tomorrow I Year: 2011 Differential ion mobility spectrometry for detection of metabolites in exhaled breath in airway diseases Source: Annual Congress 2009 - Airway inflammation and asthma control Year: 2009 Differential ion mobility spectrometry (DMS) for use in non invasive diagnostic from exhaled air Source: Annual Congress 2010 - Exhaled biomarkers: smells like disease Year: 2010 Adaptation of differential ion mobility spectrometry (DMS) for discrimination of specific biomarkers in exhaled breath in patients with severe renal-pulmonary dysfunction Source: Annual Congress 2011 - Bronchial hyperresponsiveness and exhaled and sputum biomarkers Year: 2011 Phenotyping of patients with COPD from exhaled air by ion mobility spectrometry Source: Annual Congress 2012 - COPD monitoring in stable disease and during exacerbation Year: 2012 Exhaled breath analysis by ion mobility spectrometry in children with asthma and cystic fibrosis Source: International Congress 2018 – Cystic fibrosis in paediatric patients: current research Year: 2018 Discrimination of protein and peptide composition of exhaled breath condensate in patients with pulmonary disease by mass spectrometry Source: Annual Congress 2011 - Role of the biomarkers in airway diseases Year: 2011 Does mass spectrometric breath analysis detect Pseudomonas aeruginosa in cystic fibrosis? Source: Eur Respir J 2016; 47: 994-997 Year: 2016 Breath analysis by ion mobility spectrometry allows to discriminate COPD from lung cancer patients. Source: International Congress 2018 – Lung cancer: from early diagnosis to modern monitoring strategies Year: 2018 Breath analysis by ion mobility spectrometry in COPD and lung cancer patients Source: Annual Congress 2009 - Quality control in lung function and new developments Year: 2009 Determination of volatile organic compounds in exhaled breath of patients with chronic obstructive pulmonary disease by gas chromatography mass spectrometry Source: Annual Congress 2010 - Exhaled biomarkers: smells like disease Year: 2010 Multicapillary ion mobility spectrometry (MCC-IMS) for early identification of bacteria in vitro Source: International Congress 2017 – How can microbiology and translational research help physicians? Year: 2017 Ion mobility spectrometry in medical diagnostics: proof of inflammation markers in different parliamentary groups of the exhaled breath Source: Annual Congress 2008 - Assessment of the respiratory system Year: 2008 Analysis of trace metal contamination in supplies used for exhaled breath condensate collection (EBC) using inductively coupled plasma-mass spectrometry (ICPMS) Source: Eur Respir J 2004; 24: Suppl. 48, 679s Year: 2004 Liquid chromatography-mass spectrometry (LC/MS) detects biomarker proteins in exhaled breath condensate (EBC) from endotracheally intubated patients collected at the exhaust port of a ventilator Source: Eur Respir J 2006; 28: Suppl. 50, 549s Year: 2006